We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVST Stock Explained for 2026 Growth Drivers and Risks
Read MoreHide Full Article
Key Takeaways
NVST says dental demand was stable to slightly improving in Q1 2026, led by double-digit category growth.
Envista expanded gross margin 100 bps and adj. EBITDA margin 120 bps as R&D rose 18.6% to $30M.
Envista repurchased $42.6M in Q1 and added $300M to buybacks; watch tariffs, China implants, and FX.
Envista Corporation (NVST - Free Report) is set up for steady value creation as it executes across growth, operational excellence, and people priorities. The company is using a productivity playbook to protect margins while spending more on innovation to support consistent product launches.
At $22.94 as of 06/02/2026, the shares sit below a 6–12 month price target of $24, framing a balanced risk-reward profile. NVST carries a Zacks Rank #3 (Hold).
NVST Snapshot and What the Report Says Now
Envista’s near-term setup is built around repeatable execution rather than a single standout quarter. The strategy centers on driving growth in core dental categories, tightening operations through a structured system, and strengthening talent development to support continuous improvement.
That positioning supports a measured upside case. The 6–12 month target of $24 versus the $22.94 stock price as of 06/02/2026 points to incremental appreciation potential, while macro volatility, tariffs, and competition keep the stance balanced.
In the past year, NVST shares have gained 22.4% against the industry’s 30.9% decline.
Image Source: Zacks Investment Research
Envista Business Mix That Investors Are Actually Buying
Envista operates through two segments that map cleanly to demand across the dental workflow. Specialty Products and Technologies generated 64.4% of 2025 revenue and includes implants, regenerative solutions, prosthetics, and associated treatment software, along with orthodontic brackets, aligners, and lab products.
Equipment and Consumables represented 35.6% of 2025 revenue and spans digital imaging systems, software and visualization solutions, endodontic systems, restorative materials, rotary burs, impression and bonding materials, cements, and infection prevention products. The breadth across implants, orthodontics, imaging, consumables, and software helps diversify demand drivers.
NVST Demand Signals From Q1 2026
Management described the dental market as stable to slightly improving in the first quarter of 2026, and category performance supported that view. Orthodontics, consumables, and diagnostics each delivered double-digit growth in the quarter, while implants grew at a mid-single-digit rate excluding China.
Growth was broad-based across both segments and most regions, with volume expansion and pricing both contributing. Developed markets led, with North America and Europe posting double-digit gains, while developing markets grew at a high-single-digit pace excluding China-related softness.
The Envista Business System is the core lever behind productivity and margin discipline, and it showed up in profitability metrics in the first quarter. Envista delivered 100 basis points of gross margin expansion and 120 basis points of adjusted EBITDA margin improvement, reflecting better operating leverage and execution.
At the same time, the company is spending more to sustain innovation, with research and development up 18.6% year over year to $30.0 million in the first quarter. Tariff costs rose $11 million year over year, but supply chain actions, selling, general and administrative discipline, and pricing initiatives helped offset the headwind.
The Zacks Consensus Estimate for NVST’s 2026 sales and loss per share implies a year-over-year improvement of 5.1% and 20.2%, respectively. The bottom-line estimates have moved north in the past 60 days.
Image Source: Zacks Investment Research
Envista Financial Profile and Shareholder Moves
Envista ended the first quarter with $1.08 billion in cash and cash equivalents, no current debt, and $1.44 billion of long-term debt, down slightly from $1.45 billion in the prior quarter. Management continues to target approximately 100% free-cash-flow conversion for 2026, even as cash flow remains seasonally weakest early in the year.
Capital return is also part of the plan. Envista repurchased about $42.6 million of stock in the first quarter, and the board authorized an incremental $300 million addition to the repurchase authorization.
NVST The Big Risks to Monitor Into 2H 2026
First, macro uncertainty and geopolitics can pressure dental utilization and purchasing cycles, especially for equipment decisions that are easier to defer. China is a specific swing factor for implants as channel partners adjust inventories ahead of anticipated volume-based procurement, which management expects to begin between the second and third quarters.
Second, tariffs remain an ongoing cost headwind, with similar quarterly levels anticipated through 2026, and competition is intense in markets shaped by rapid technological change and pricing pressure. Consistent new-product traction is essential to sustain growth while Envista reinvests at double-digit rates in sales, marketing, and research and development. Foreign exchange is another variable given that 52.7% of first-quarter 2026 revenue came from outside the United States.
View the Zacks #1 Rank List
Image: Bigstock
NVST Stock Explained for 2026 Growth Drivers and Risks
Key Takeaways
Envista Corporation (NVST - Free Report) is set up for steady value creation as it executes across growth, operational excellence, and people priorities. The company is using a productivity playbook to protect margins while spending more on innovation to support consistent product launches.
At $22.94 as of 06/02/2026, the shares sit below a 6–12 month price target of $24, framing a balanced risk-reward profile. NVST carries a Zacks Rank #3 (Hold).
NVST Snapshot and What the Report Says Now
Envista’s near-term setup is built around repeatable execution rather than a single standout quarter. The strategy centers on driving growth in core dental categories, tightening operations through a structured system, and strengthening talent development to support continuous improvement.
That positioning supports a measured upside case. The 6–12 month target of $24 versus the $22.94 stock price as of 06/02/2026 points to incremental appreciation potential, while macro volatility, tariffs, and competition keep the stance balanced.
In the past year, NVST shares have gained 22.4% against the industry’s 30.9% decline.
Image Source: Zacks Investment Research
Envista Business Mix That Investors Are Actually Buying
Envista operates through two segments that map cleanly to demand across the dental workflow. Specialty Products and Technologies generated 64.4% of 2025 revenue and includes implants, regenerative solutions, prosthetics, and associated treatment software, along with orthodontic brackets, aligners, and lab products.
Equipment and Consumables represented 35.6% of 2025 revenue and spans digital imaging systems, software and visualization solutions, endodontic systems, restorative materials, rotary burs, impression and bonding materials, cements, and infection prevention products. The breadth across implants, orthodontics, imaging, consumables, and software helps diversify demand drivers.
NVST Demand Signals From Q1 2026
Management described the dental market as stable to slightly improving in the first quarter of 2026, and category performance supported that view. Orthodontics, consumables, and diagnostics each delivered double-digit growth in the quarter, while implants grew at a mid-single-digit rate excluding China.
Growth was broad-based across both segments and most regions, with volume expansion and pricing both contributing. Developed markets led, with North America and Europe posting double-digit gains, while developing markets grew at a high-single-digit pace excluding China-related softness.
Envista Execution Engine Behind Margin Improvement
The Envista Business System is the core lever behind productivity and margin discipline, and it showed up in profitability metrics in the first quarter. Envista delivered 100 basis points of gross margin expansion and 120 basis points of adjusted EBITDA margin improvement, reflecting better operating leverage and execution.
At the same time, the company is spending more to sustain innovation, with research and development up 18.6% year over year to $30.0 million in the first quarter. Tariff costs rose $11 million year over year, but supply chain actions, selling, general and administrative discipline, and pricing initiatives helped offset the headwind.
The Zacks Consensus Estimate for NVST’s 2026 sales and loss per share implies a year-over-year improvement of 5.1% and 20.2%, respectively. The bottom-line estimates have moved north in the past 60 days.
Image Source: Zacks Investment Research
Envista Financial Profile and Shareholder Moves
Envista ended the first quarter with $1.08 billion in cash and cash equivalents, no current debt, and $1.44 billion of long-term debt, down slightly from $1.45 billion in the prior quarter. Management continues to target approximately 100% free-cash-flow conversion for 2026, even as cash flow remains seasonally weakest early in the year.
Capital return is also part of the plan. Envista repurchased about $42.6 million of stock in the first quarter, and the board authorized an incremental $300 million addition to the repurchase authorization.
NVST The Big Risks to Monitor Into 2H 2026
First, macro uncertainty and geopolitics can pressure dental utilization and purchasing cycles, especially for equipment decisions that are easier to defer. China is a specific swing factor for implants as channel partners adjust inventories ahead of anticipated volume-based procurement, which management expects to begin between the second and third quarters.
Second, tariffs remain an ongoing cost headwind, with similar quarterly levels anticipated through 2026, and competition is intense in markets shaped by rapid technological change and pricing pressure. Consistent new-product traction is essential to sustain growth while Envista reinvests at double-digit rates in sales, marketing, and research and development. Foreign exchange is another variable given that 52.7% of first-quarter 2026 revenue came from outside the United States.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.